Skip directly to site content

Home > Quality of Care > Use of Medications in CKD > Percentage of Patients With CKD and Diabetes Using SGLT2i

Percentage of Patients With CKD and Diabetes Using SGLT2i

Percentage of Patients With CKD and Diabetes Using SGLT2i

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is higher among adults with diabetes in early stages of chronic kidney disease (CKD) (stage 1: 14%, stage 2: 14.2%) than those in more advanced stages of CKD (stage 3: 10.2%, stage 4: 2.9%, and stage 5: 3.8%).

Data Source: Clinformatics Commercial


Sort By:

+ View Data Table

CKD determined by ICD-9-CM and ICD-10-CM diagnosis codes. Data are not adjusted.

Clinformatics data sets provide paid medical and prescription claims and enrollment information for participants in commercial insurance plans and Medicare Advantage plans. The sample was limited to those enrolled in their health plan for all 12 months of the calendar year. Chronic kidney disease (CKD) and diabetes are defined using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), or Tenth Revision (ICD-10-CM) diagnosis codes. Outpatient pharmacy records of prescriptions filled for patients were examined for drugs in the sodium-glucose cotransporter-2 (SGLT2) inhibitors class. For inclusion in analyses, beneficiaries had to be in the enrollment file. To define CKD, diabetes, or hypertension, at least one inpatient or two outpatient claims were used.

Description of Measure

The percentage of patients diagnosed with CKD and diabetes that received sodium-glucose cotransporter-2 inhibitor (SGLT2i) drugs.

Data Set

Clinformatics Commercial from Optum Clinformatics Data Mart Database (OptumInsight, Eden Prairie, MN).


Privately insured employed patients aged 20–64 years with at least one inpatient or two outpatient claims during the calendar year.

Years Included



Patients aged 20–64 years with prescription for SGLT2i identified by generic name and National Drug Code (NDC).


Patients aged 20–64 years enrolled in Clinformatics Commercial insurance and diagnosed with CKD and diabetes.

Definition of CKD

ICD-9-CM and ICD-10-CM diagnosis codes.

ICD-10-CM Codes for CKD

A18.11, A52.75, B52.0, C64.x, C68.9, D30.0x, D41.0x-D41.2x, D59.3, E08.2x, E09.2x, E10.2x, E10.65, E11.2x, E11.65, E13.2x, E74.8, I12.xx, I13.0, I13.1x, I13.2, K76.7, M10.3x, M32.14, M32.15, N01.x-N08.x, N13.1, N13.1x-N13.39, N14.x,N15.0, N15.8, N15.9, N16, N17.x, N18.1-N18.5, N18.8, N18.9, N19, N25.xx, N26.1, N26.9, O10.4xx, O12.xx, O26.83x, O90.89, Q61.02, Q61.1x-Q61.8, Q26.0-Q26.39, R94.4 (x and xx stand for all the codes within the main diagnosis).

ICD-9-CM Codes for CKD

016.0, 095.4, 189.0,189.1, 189.9, 236.91, 250.4, 250.41, 250.42, 250.43, 271.4, 274.10, 283.11, 403.xx, 404.xx, 405.01, 405.11, 440.1, 442.1, 447.3, 453.3, 573.4, 580.xx, 581.xx, 582.xx, 583.xx, 584.5, 585.x, 587.xx, 588.xx, 590.xx, 591, 592.x, 593.xx, 642.1, 646.2, 753.xx, 794.4.

SGLT2 drugs

canagliflozin, dapagliflozin, empagliflozin, ertugliflozin.


Diabetes is determined by the presence of an ICD-9-CM code (250.xx, 357.2, 336.41, 362.01, 362.02) or ICD-10-CM (E08.xx, E09.xx, E10.xx, E11.xx, E13.xx) for diabetes on at least one inpatient or outpatient claim during the given calendar year.


Hypertension is determined by the presence of an ICD-9-CM code (401.x through 405.x) or ICD-10-CM code (H35.03x, I10.xx, I11.xx, I12.xx, I13.xx,, I67.4, N26.2) for hypertension on at least one inpatient or outpatient claim during the given calendar year.

Limitations of Indicator

As a measure of prevalence, the use of ICD-9-CM or ICD-10-CM diagnosis codes will underestimate CKD.

Analytical Considerations

Care must be taken in comparisons based on diagnosis code-based definitions of CKD and diabetes.

eGFR Formula Disclaimer
At the time of the last data update in summer 2022, the race-free eGFR formula was newly recommended and impact on health outcomes is underway. To avoid inconsistent results caused by different formulae, stakeholders continued using the eGFR formula with race during this transition. Since then, comparisons have been made. The estimates for the current website launch are still based on analyses using the eGFR formula with race, however plan is to use race-free eGFR formula for the next data update and upcoming website launch in fall 2023.